Reimbursement Review Reports

( Last Updated : February 3, 2023)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Mvasi Bevacizumab mCRC NSCLC Biosimilar N/A Complete
Ikervis cyclosporine keratitis, severe Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
Fulphila pegfilgrastim Febrile neutropenia in non-myeloid malignancies N/A Complete
Semglee insulin glargine Diabetes mellitus, Type 1 & 2 Withdrawn
TBC filgrastim Cancelled
Ogivri Trastuzumab Withdrawn
Zytiga Abiraterone Withdrawn
Admelog Insulin lispro Cancelled